1. A method of treating a subject suffering from ischemic injury or an acute ischemic event, comprising administering to the subject cysteamine, a cysteamine derivative, cystamine, a cystamine derivative or a pharmaceutically acceptable salt thereof in an amount effective to reduce ischemic damage. The method of claim 1, wherein the ischemic damage is the result of a thrombotic disease. The method of claim 2, wherein the thrombotic disease is sickle cell anemia, deep vein thrombosis, pulmonary embolism, cardiac embolism, hypercoagulation state, thrombophilia, Lyaden factor V, antithrombin III deficiency, protein C deficiency, protein S deficiency, prothrombin 2 mutation (G20 gene mutation (G20 ), hyperhomocysteinemia, antiphospholipid antibody syndrome (APS), anticardiolipin antibody syndrome (ACLA), or lupus anticoagulant syndrome (LA). 4. The method according to any one of paragraphs. 1-3, in which the amount of cysteamine, a cysteamine derivative, cystamine, a cystamine derivative or a pharmaceutically acceptable salt thereof is effective to reduce the risk of ischemic damage resulting from thrombosis. 5. The method of claim 1, wherein the subject has cancer, myeloproliferative disease, multiple myeloma, underwent surgery, has been injured, is in a state of immobilization, takes an oral contraceptive, thalidomide or its related compounds are administered to the subject optionally in combination with a steroid hormone, has heparin-induced thrombocytopenia, is pregnant, has inflammatory bowel disease, has nephrotic syndrome, has nocturnal1. Способ лечения субъекта, страдающего от ишемического повреждения или острого ишемического события, включающий введение субъекту цистеамина, производного цистеамина, цистамина, производного цистамина или их фармацевтически приемлемой соли в количестве, эффективном для уменьшения ишемического повреждения.2. Способ по п. 1, в котором ишемическое повреждение является результатом тромботического заболевания.3. Способ по п. 2, в котор
